Selected advances in tumor targeted anthracyclines
| Carrier | Conjugate | Investigational or Approved Indications |
|---|---|---|
| Liposomes | ||
| Pegylated (Doxil - Caelyx) | — | Ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma, high grade gliomas, glioblastoma or secondary brain tumors, head and neck squamous cell cancer, breast cancer, squamous cell carcinoma of the cervix |
| Uncoated, citrate-containing | — | Breast cancer |
| [Evacet - Myocet (TLC D-99)] | ||
| Uncoated (DaunoXome) | — | AIDS-related Kaposi's sarcoma, acute myeloblastic leukaemia, multiple myeloma, non-Hodgkin's lymphoma, breast cancer |
| Immunoliposomes | ||
| Pegylated or uncoated | Fab' fragments of trastuzumab | Breast cancer |
| Pegylated | anti-MUC-1 monoclonal antibody | Breast cancer |
| Pegylated | anti-CD19 monoclonal antibody | Multiple myeloma |
| Pegylated | Anti-GD(2) ganglioside whole antibodies | Neuroblastoma |
| Pegylated | Anti-aminopeptidase-N NGR peptide | Neuroblastoma |
| Peptides or copolymers | ||
| L-377,202 | N-glutaryl-[4-hydroxyprolyl]-Ala-Ser-cyclohexaglycyl-Glu-Ser-Leu | Prostate cancer |
| CPI-0004Na | (N-Succinyl-Ala-Ala-Leu) | Breast cancer, prostate cancer |
| Uncoded | Integrin-targeted RGD-4C peptide + plasmin-targeted (Ala-Phe-Lys) | Fibrosarcoma |
| PK2 | tetrapeptide linked to to galactosamine-containing N-(2-hydroxypropyl) methacrylamide copolymers | Primary or metastatic liver cancer |
All formulations contain DOX, except DaunoXome, which contains DNR.
MUC-1, mucin-1 antigen.